Experts say Australia should be able to reopen border as long as vaccines prove effective against severe disease – because that’s what kills people
- Australia Covid vaccine tracker: how is the rollout progressing and when will you get the jab?
- Australian-produced AstraZeneca vaccines will address ‘drastic shortages’
- Aboriginal health sector overcoming major challenges to deliver first jabs
The results from AstraZeneca’s US phase 3 clinical trials for its Covid vaccine were made available this week with the vaccine showing 100% efficacy against severe or critical disease and hospitalisation. It showed 80% efficacy in those aged 65 years and over and, overall, had 79% efficacy at preventing symptomatic Covid-19.
These interim safety and efficacy results were based on 32,449 participants who had between them 141 symptomatic cases of Covid-19, and although questions about some aspects of the study are now being raised in the US, the good results largely mirror those of previous clinical trials.
Read the original article at The Guardian